Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.48 |
| ▸ | MAOA | P21397 | 9/20 | 0.48 |
| ▸ | CALML3 | P27482 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564164 | 1.00 | MAOB (0.48) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL14302608 | 0.87 | MAOB (0.48) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL14574048 | 0.87 | MAOB (0.48) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL8111357 | 0.87 | CALML3 (0.64) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5832684 | 0.87 | CALML3 (0.64) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL4013373 | 0.87 | MAOB (0.50) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5832691 | 0.87 | CALML3 (0.64) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5231103 | 0.83 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL7830574 | 0.83 | MAOA (0.68) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL7830571 | 0.83 | MAOA (0.68) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070270357-A1 | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | MAOB 1276/4885MAOA 999/4885CALML3 3775/4885 |
| US-20070270357-A1 | Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same | PAICS, MAP2K4, GIPR | MAOB 1137/4885MAOA 1209/4885CALML3 4616/4885 |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | PAICS, MAP2K4, GIPR | MAOB 1137/4885MAOA 1209/4885CALML3 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.